A Systematic Review of Cost Reduction Techniques for Mutation Testing: Preliminary Results

Background: Ongoing clinical trials are investigating poly(ADP-ribose) polymerase (PARP) inhibitors to target the DNA damage repair (DDR) pathway in prostate cancer. DDR mutation screening will guide treatment strategy and assess eligibility for clinical trials. Materials & methods: This systematic review estimated the rate of DDR mutation testing or genetic counseling among men with or at risk of prostate cancer. Results: From 6856 records, one study fulfilled the inclusion criteria and described men undiagnosed with prostate cancer with a family history of BRCA1/2 mutation who received DDR mutation testing. Conclusion: With only one study included in this first systematic review of DDR mutation testing or genetic counseling in men with or at risk of prostate cancer, more research is warranted.

Download Full-text

AB0116 THE EFFECTS OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON PATIENT REPORTED OUTCOMES; PRELIMINARY RESULTS OF A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.1578 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 1087.1-1087

Author(s):

M. Van den Dikkenberg, Msc ◽

N. Luurssen-Masurel ◽

M. Kuijper ◽

M. R. Kok ◽

P. De Jong ◽

...

Keyword(s):

Systematic Review ◽

Patient Reported Outcomes ◽

Treatment Effects ◽

Meta Analysis ◽

Activity Limitations ◽

Definitive Answer ◽

Preliminary Results ◽

Patient Reported ◽

Standard Set ◽

Disease Modifying

Background:The need to involve patient reported outcomes (PROs) in the management of rheumatoid arthritis (RA) increases, since PROs quantify patient relevant outcomes. Although PROs have been incorporated in the core-outcome sets in clinical trials, knowledge about the treatment effects on these PROs is scarce. Therefore, we performed a systematic review on the effects of disease modifying anti-rheumatic drugs (DMARDs), of any type, on relevant PRO domains mentioned in the ICHOM standard set. This might support rheumatologists and RA patients during treatment decisions.Objectives:To get insight in the treatment effects of DMARDs of any type on three PRO domains that matter to patients (pain, activity limitations and fatigue).Methods:A systematic review was performed in Embase, Medline, Web of Science, Cochrane and Google Scholar. Included were all studies that were published before August 2019 and showed DMARD treatment effects in RA on PROs that are part of the ICHOM standard set. Three Bayesian network meta-analyses were performed for the PRO domains pain, activity limitations and fatigue. Preliminary results of DMARDs (in)directly compared to placebo were visualized by forest plots using R.Results:The search strategy yielded n=5974 articles. After selection was performed by 2 independent researchers, n=70 individual articles representing n=53 studies were extracted, over the three PRO domains; pain (n=31), activity limitations (n=41) and fatigue (n=21). In all RCTs, PROs were only reported as secondary or tertiary endpoints. In figure 1, we show the effects on PROs for any type of DMARD investigated compared to placebo. Overall, DMARDs show a greater reduction in pain (standardized mean difference (SMD); -0.97 – -0.22) and most of them in activity limitations (SMD; -0.81 – 0.56). In fatigue, this clear direction is lacking (SMD; -0.86 – 3.5). csDMARDs and anti-TNF seem to perform slightly, but nog significantly, worse than other bDMARDs and tsDMARDs in the first two domains.Conclusion:Within in this systematic review we report a reduction for DMARDs of any type on the domains of pain and activity limitations compared to placebo. However, results are still preliminary and should be interpreted with care. A more comprehensive network analysis might give a more definitive answer which DMARD performs best.Figure 1.Disclosure of Interests:None declared

Download Full-text

Investigating Different Metrics for Evaluation and Selection of Mutation Operators for Java

International Journal of Software Engineering and Knowledge Engineering ◽

10.1142/s021819402150011x ◽

2021 ◽

Vol 31 (03) ◽

pp. 311-336

Author(s):

Shweta Rani ◽

Bharti Suri

Keyword(s):

Cost Reduction ◽

Test Suite ◽

Cost Benefits ◽

Powerful Technique ◽

Reduction Techniques ◽

Mutation Operators ◽

Different Types ◽

Java Programs ◽

Selective Mutation ◽

Selection Of

Mutation testing is a successful and powerful technique, specifically designed for injecting the artificial faults. Although it is effective at revealing the faults, test suite assessment and its reduction, however, suffer from the expense of executing a large number of mutants. The researchers have proposed different types of cost reduction techniques in the literature. These techniques highly depend on the inspection of mutation operators. Several metrics have been evolved for the same. The selective mutation technique is most frequently used by the researchers. In this paper, the authors investigate different metrics for evaluating the traditional mutation operators for Java. Results on 13 Java programs indicate how grouping few operators can impact the effectiveness of an adequate and minimal test suite, and how this could provide several cost benefits.

Download Full-text

Preliminary Results of a Systematic Review: Quality Assessment of Conversational Agents (Chatbots) for People with Disabilities or Special Needs

Lecture Notes in Computer Science - Computers Helping People with Special Needs ◽

10.1007/978-3-030-58796-3_30 ◽

2020 ◽

pp. 250-257

Author(s):

Maria Laura de Filippis ◽

Stefano Federici ◽

Maria Laura Mele ◽

Simone Borsci ◽

Marco Bracalenti ◽

...

Keyword(s):

Systematic Review ◽

Quality Assessment ◽

Special Needs ◽

People With Disabilities ◽

Conversational Agents ◽

Preliminary Results

Download Full-text

Economic consequences to society of pandemic H1N1 influenza 2009 – preliminary results for Sweden

Eurosurveillance ◽

10.2807/ese.14.37.19333-en ◽

2009 ◽

Vol 14 (37) ◽

Cited By ~ 17

Author(s):

L Brouwers ◽

B Cakici ◽

M Camitz ◽

A Tegnell ◽

M Boman

Keyword(s):

Cost Reduction ◽

Cost Effective ◽

H1n1 Influenza ◽

Economic Consequences ◽

Pandemic H1n1 ◽

Preliminary Results ◽

Pandemic H1n1 Influenza ◽

Swedish Society ◽

The Cost ◽

Death Cases

Experiments using a microsimulation platform show that vaccination against pandemic H1N1 influenza is highly cost-effective. Swedish society may reduce the costs of pandemic by about SEK 2.5 billion (approximately EUR 250 million) if at least 60 per cent of the population is vaccinated, even if costs related to death cases are excluded. The cost reduction primarily results from reduced absenteeism. These results are preliminary and based on comprehensive assumptions about the infectiousness and morbidity of the pandemic, which are uncertain in the current situation.

Download Full-text